IASO Bio gains Hong Kong approval for Fucaso application
Fucaso's approval in Hong Kong is the first authorisation for a China-developed CAR-T cell therapy.
Drug Development
MHRA approves Roche’s inavolisib for breast cancer
BeOne’s sonrotoclax gains priority FDA review for mantle cell lymphoma
Corstasis Therapeutics partners CVL for Enbumyst integration
UNICEF and Gavi to widen affordable malaria vaccine access
FDA grants accelerated approval for Otsuka’s IgAN therapy
Novartis secures approval from FDA for Itvisma to treat SMA
FDA awards record number of review designations to ADCs in 2024
